Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Business Wire•22/10/2026•07:30 ET
0
Key Highlights
- ➤Verastem will report third-quarter 2026 financial results November 5, 2026
- ➤Conference call and webcast scheduled for 4:30 pm ET
- ➤Verastem markets AVMAPKI FAKZYNJA CO-PACK in the U.S.
- ➤Pipeline targets RAF/MEK, FAK, and KRAS G12D signaling pathways
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET.
Get started
Create a free account to read the full story.